A Surgical "Window-of-Opportunity" and Phase II Trial of Pembrolizumab, Olaparib and Temozolomide in Recurrent Glioblastoma
This research study is testing a combination of three medications—pembrolizumab, olaparib, and temozolomide—to see how well they work against a fast-growing brain tumor called recurrent glioblastoma. The goal is to find new and more effective ways to help patients when their tumor has returned after previous treatments.
You may be eligible if you are 18 years or older, are well enough to handle daily activities, and have a glioblastoma that has returned after earlier treatment. You must also be able to understand the study details, follow the schedule, and keep a daily medicine diary.
Participants will receive a combination of study medications, which include immunotherapy, a targeted cancer drug, and chemotherapy. You will need to carefully follow the medication schedule, keep track of your doses in a daily diary, and attend regular check-ins with the study team.
This study takes place in Boston, Massachusetts. The study is currently active, but it is not actively looking for new participants right now.
- 1Tests a combination of three different cancer-fighting medications for recurrent brain tumors.
- 2Requires participants to be 18 or older and able to maintain daily activities.
- 3Involves taking study medications and keeping a daily medicine diary.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.